Treatment with Helicobacter pylori-derived VacA attenuates allergic airway disease.

ABSTRACT:

Background

Asthma is an incurable heterogeneous disease with variations in clinical and underlying immunological phenotype. New approaches could help to support existing therapy concepts. Neonatal infection of mice with Helicobacter pylori or administration of H. pylori-derived extracts or molecules after birth have been shown to prevent the development of allergic airway disease later in life. This study evaluated the potential therapeutic efficacy of H. pylori vacuolating cytotoxin A (VacA) in allergic airway inflammation and investigated the underlying immunological mechanisms for its actions.

Methods

Murine models of allergic airway diseases, and murine and human in vitro models were used.

Results

In both an acute model and a therapeuti

SUBMITTER: Reuter S 

PROVIDER: S-EPMC9902502 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature